Evidence map›Paper›PMID 26984729›Full record

ArticleJournal of virology2016

Cellular Immune Responses against Simian T-Lymphotropic Virus Type 1 Target Tax in Infected Baboons.

Iris Castro, Teresa M Giret, Diogo M Magnani, Helen S Maxwell, Oliver Umland, Jessica K Perry, Jerilyn K Pecotte, Kathleen M Brasky, Glen N Barber, Ronald C Desrosiers and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Iris CastroDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Teresa M GiretDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Diogo M MagnaniDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Helen S MaxwellDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Oliver UmlandDiabetes Research Institute, Flow Cytometry Core, University of Miami Miller School of Medicine, Miami, Florida, USA.
Jessica K PerrySouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Jerilyn K PecotteSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Kathleen M BraskySouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Glen N BarberDepartment of Cell Biology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Ronald C DesrosiersDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, USA.
David I WatkinsDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, USA dwatkins@med.miami.edu.
University of Miami · USTexas Biomedical Research Institute · US

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
WNV REPLIVAX VACCINE IN NON-HUMAN PRIMATESP51RR013986 · NCRR · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI GAUDUIN, MARIE-CLAIRE ELISABETH · 1999 to 2011
$79.1M
NCRR NIH HHS P51 RR013986NIH HHS P51 OD011133
6 · The paper itself

Abstract

unlabelledThere are currently 5 million to 10 million human T-lymphotropic virus type 1 (HTLV-1)-infected people, and many of them will develop severe complications resulting from this infection. A vaccine is urgently needed in areas where HTLV-1 is endemic. Many vaccines are best tested in nonhuman primate animal models. As a first step in designing an effective HTLV-1 vaccine, we defined the CD8(+) and CD4(+) T cell response against simian T-lymphotropic virus type 1 (STLV-1), a virus closely related to HTLV-1, in olive baboons (Papio anubis). Consistent with persistent antigenic exposure, we observed that STLV-1-specific CD8(+) T cells displayed an effector memory phenotype and usually expressed CD107a, gamma interferon (IFN-γ), and tumor necrosis factor alpha (TNF-α). To assess the viral targets of the cellular immune response in STLV-1-infected animals, we used intracellular cytokine staining to detect responses against overlapping peptides covering the entire STLV-1 proteome. Our results show that, similarly to humans, the baboon CD8(+) T cell response narrowly targeted the Tax protein. Our findings suggest that the STLV-1-infected baboon model may recapitulate some of the important aspects of the human response against HTLV-1 and could be an important tool for the development of immune-based therapy and prophylaxis. IMPORTANCE: HTLV-1 infection can lead to many different and often fatal conditions. A vaccine deployed in areas of high prevalence might reduce the incidence of HTLV-1-induced disease. Unfortunately, there are very few animal models of HTLV-1 infection useful for testing vaccine approaches. Here we describe cellular immune responses in baboons against a closely related virus, STLV-1. We show for the first time that the immune response against STLV-1 in naturally infected baboons is largely directed against the Tax protein. Similar findings in humans and the sequence similarity between the human and baboon viruses suggest that the STLV-1-infected baboon model might be useful for developing a vaccine against HTLV-1.

Indexed as

Immunity, CellularAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDeltaretrovirus InfectionsDisease Models, AnimalDrug DiscoveryGene Products, taxHumansImmunologic MemoryInterferon-gammaPapioProteomeSimian T-lymphotropic virus 1Tumor Necrosis Factor-alphaViral LoadGene Products, taxInterferon-gammaProteomeTumor Necrosis Factor-alphaViral Vaccines

Identifiers

PMID26984729
PMCPMC4934758
OpenAlexW2300952637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.